Dr. Yakun Wan is the founder of Shanghai sdAb Bio-pharmaceutical Technology Co., Ltd. and the current CEO of the company. He once served as a researcher and doctoral supervisor at the Shanghai Institute of Pharmaceutical Research, Chinese Academy of Sciences, and a professor at Southeast University. At the same time, he also served as the director of Jiangsu Nanoantibody Engineering Technology Research and Development Center. He has successively engaged in post-doctoral research at the University of Texas at Austin, Baylor College of Medicine and the American Institute of Systems Biology, and served as a researcher at the American Institute of Systems Biology.

Dr. Wan has been committed to the research of sdAb for 16 years, has extremely rich experience in sdAb projects, and enjoys a high reputation and popularity in the field of sdAb. He has been selected in the "Hundred Talents Plan" of the Shanghai Institute of Medicine, Chinese Academy of Sciences, won the six talent peak plans of Jiangsu Province, the "High-level Creative Talents Plan" of the Ministry of Education, and the "New Century Excellent Talents" "Outstanding innovation and entrepreneurship talents in Zhangjiang National Independent Innovation Demonstration Zone in 2021" and other honorary titles. Novamab was selected as one of the top 50 most innovative pharmaceutical enterprises in China in 2020 and the top 100 pharmaceutical innovative seed enterprises in China in 2022.

In the field of scientific research, Dr. Wan has published more than 60 scientific research papers in recent years, including more than 50 SCI academic papers as the first author and corresponding author, and published research results on the regulation of chromatin structure by nuclear porin in the top international academic journal Cell, which provides scientific basis and research basis for human exploration of cell aging and related diseases. In recent years, Dr. Wan has applied for more than 80 invention patents at home and abroad, of which 61 have been published and 30 have been authorized. At the same time, as the project leader, he has undertaken a number of key projects in Shanghai and the National Natural Science Foundation, such as the Shanghai Science and Technology Innovation Fund for Small and Medium-sized Enterprises, the Shanghai Intellectual Property Office Patent Navigation Project, the Shanghai Biomedical Science and Technology Support Project, the Shanghai Patent Work Pilot, and the National Natural Science Foundation General Project.

In the field of new drug research and development, Dr. Wan has set up China's first sdAb research and development team, and has successfully cooperated with many well-known pharmaceutical companies at home and abroad. Many of the cooperative products have been promoted to different stages of clinical research, with excellent clinical performance. With a complete R&D, pilot test and GMP production system, Novamab is the only company in China that has the ability to develop the whole process of sdAb. In addition, the production of sdAb 500L Pichia pastoris GMP pilot production workshop fills the industry gap in this field, which is extremely scarce and competitive. The LQ036 project, based on the Pichia pastoris expression platform sdAb and the research and development platform of inhaled biological drugs, is positioned as the first inhaled sdAb asthma treatment drug in the world. It has entered Phase I clinical in Australia in June 2021, and human experiments have shown excellent safety; In January 2022, the Chinese clinical phase I IND of the project has also been officially approved (Notice No.: 2022LP00124), and the Chinese clinical phase I will be carried out simultaneously in 2022. LQ043, an innovative drug for respiratory diseases, also entered the IND declaration in 2022. In addition, Rocky Biology will ensure that 1-2 projects are promoted to the clinical research stage every year.